×
Hero Background

Hereditary Angioedema Therapeutics Companies

ID: MRFR/HC/10642-HCR
128 Pages
Rahul Gotadki
October 2025

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling (edema), typically in the limbs, face, gastrointestinal tract, and airway. The condition is caused by a deficiency or dysfunction of C1 esterase inhibitor (C1-INH), a protein involved in regulating inflammation and the immune response. The swelling episodes can be spontaneous or triggered by stress, trauma, surgery, or infection.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Hereditary Angioedema Therapeutics Market Research Report—Global Forecast till 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Hereditary Angioedema Therapeutics Market

Hereditary Angioedema Therapeutics Key Companies

 


Latest Hereditary Angioedema Therapeutics Companies Update:

BioCryst Pharmaceuticals Received FDA approval for Orladeyo™ (berotralstat) for prophylaxis of HAE attacks, offering the first and only once-daily oral medication for this indication.Announced positive late-stage clinical trial results for beronalstat in pediatric HAE patients, potentially expanding its market reach.


Takeda Pharmaceutical Company Launched Takhzyro™ (lanadelumab) in the US, providing a long-acting subcutaneous injection for HAE prophylaxis.Initiated Phase 3 clinical trials for its novel C5a receptor inhibitor TAK-994 for HAE prevention, expanding its treatment pipeline.


Shire Received FDA approval for Cinryze™ (C1 esterase inhibitor) for the treatment of acute HAE attacks, offering a rapid-acting intravenous option.Collaborated with patient advocacy groups to launch educational initiatives and improve access to HAE care.


Alexion Pharmaceuticals Continued to be a leader in the HAE market with its established medications Soliris™ (eculizumab) and Ultomiris™ (ravulizumab), offering long-term prevention and treatment options. Focused on expanding access to its therapies through patient assistance programs and advocacy partnerships.


List of Hereditary Angioedema Therapeutics Key companies in the market

  • Takeda Pharmaceutical Company Limited (Japan)

  • CSL Behring (US)

  • Sanofi (France)

  • BioCryst Pharmaceuticals, Inc (US)

  • Pharvaris B.V. (Switzerland)

  • Ionis Pharmaceuticals, Inc (US)

  • Pharming Group N.V. (Netherlands)

  • KalVista Pharmaceuticals, Inc (US)

  • IBio, Inc. (US)

  • BioMarin Pharmaceutical Inc (US)